Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 ...

Maxim lowered the firm’s price target on Silexion Therapeutics (SLXN) to $5 from $9 and keeps a Buy rating on the shares after its Q4 results. The company is progressing with its SIL-204 ...

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage ...

Silexion Therapeutics announces an expanded development plan for SIL204, targeting KRAS-driven cancers, to be presented at the NeauxCancer 2025 Conference. Silexion Therapeutics Corp., a ...

This page features the latest news about the Silexion Therapeutics stock. SLXN stock touches 52-week low at $1.32 amid market challenges In a turbulent market environment, SLXN stock has reached a ...

Silexion Therapeutics Corp, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, announced it has completed an expanded development plan for its ...

Silexion Therapeutics Corp. has announced an expanded development plan for its next-generation siRNA candidate SIL-204. The new dual-route strategy will integrate intratumoral and systemic ...

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...